Literature DB >> 6891640

Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions.

J Wieberdink, C Benckhuysen, R P Braat, E A van Slooten, G A Olthuis.   

Abstract

The optimal single dosage of melphalan in isolation perfusion of the limbs for malignant melanoma was assessed. For this purpose a method to determine the volume of the isolated region in the individual patient and a grading system for the reaction of the normal tissues were introduced. A strictly standardized pharmacosurgical routine was developed that permitted an analysis of the correlation between dosage and the grade of toxic reaction in 90 perfusions. The optimal dosage of a cytostatic drug was considered to be the highest amount tolerated at an acceptable risk. Melphalan at 10 mg/l perfused tissue was determined as the likely optimum. This dose provoked remarkably little variation in toxicity, all reactions falling within a safe range. No exception to the applicability of this dosage was encountered.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6891640     DOI: 10.1016/0277-5379(82)90235-8

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  60 in total

1.  A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities.

Authors:  Christy Y Chai; Jeremiah L Deneve; Georgia M Beasley; Suroosh S Marzban; Y Ann Chen; Bhupendra Rawal; Stephen R Grobmyer; Steven N Hochwald; Douglas S Tyler; Jonathan S Zager
Journal:  Ann Surg Oncol       Date:  2011-12-06       Impact factor: 5.344

Review 2.  [Current state of neoadjuvant therapy of soft tissue sarcoma].

Authors:  M Lehnhardt; T Schmitt; M Bischof; A Daigeler; G Egerer
Journal:  Chirurg       Date:  2011-11       Impact factor: 0.955

3.  Hyperthermic perfusion with chemotherapy for melanoma of the extremities.

Authors:  F Ghussen; I Krüger; R V Smalley; W Groth
Journal:  World J Surg       Date:  1989 Sep-Oct       Impact factor: 3.352

Review 4.  Regional therapies for locoregionally advanced and unresectable melanoma.

Authors:  Evan S Weitman; Jonathan S Zager
Journal:  Clin Exp Metastasis       Date:  2018-05-08       Impact factor: 5.150

5.  Initial experiences with isolated limb perfusion for unresectable melanoma of the limb.

Authors:  L Romics; E A Dy; J C Coffey; D Herlihy; F Aftab; M Z Chaudhry; K Fogarty; J A O'Donnell; H P Redmond
Journal:  Ir J Med Sci       Date:  2011-02-03       Impact factor: 1.568

6.  Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution.

Authors:  Amanda K Raymond; Georgia M Beasley; Gloria Broadwater; Christina K Augustine; James C Padussis; Ryan Turley; Bercedis Peterson; Hilliard Seigler; Scott K Pruitt; Douglas S Tyler
Journal:  J Am Coll Surg       Date:  2011-04-13       Impact factor: 6.113

7.  [Improved intraoperative leak control in cytostatic drug isolation perfusion of tumors of the extremities].

Authors:  M Manner; H Sinn; H Bubeck; C Kettelhack; P Schlag
Journal:  Langenbecks Arch Chir       Date:  1990

8.  One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases.

Authors:  Dirk J Grünhagen; Flavia Brunstein; Wilfried J Graveland; Albertus N van Geel; Johannes H W de Wilt; Alexander M M Eggermont
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

Review 9.  Regional therapies for in-transit disease.

Authors:  Paul J Speicher; Claire H Meriwether; Douglas S Tyler
Journal:  Surg Oncol Clin N Am       Date:  2015-01-30       Impact factor: 3.495

10.  Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity?

Authors:  N McMahon; T Y Cheng; G M Beasley; I Spasojevic; W Petros; C K Augustine; P Zipfel; J C Padussis; G Sanders; Douglas S Tyler
Journal:  Ann Surg Oncol       Date:  2009-01-30       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.